FDA Final Guidance on Psychedelic Drug Trials (2026)

Table of Contents

1. What the FDA Did
2. What a Guidance Is, and the Terms It Uses
3. Manufacturing and Product Quality
4. Animal Studies and the Heart-Valve Question
5. How the Body Handles the Drug: Food, Interactions and Organ Function
6. Abuse Potential and Controlled-Substance Rules
7. Trial Design: Blinding, Controls and How Long Benefits Last
8. Psychotherapy Alongside the Drug
9. Safety Monitoring During Treatment Sessions
10. The April 2026 Actions That Came First
11. The September 2026 Public Hearing
12. What These Documents Do Not Do
13. Status as of 11 October 2026
14. How It Fits the FDA’s Earlier Steps
15. Primary Documents
16. Key Research Papers
17. Connections

1. What the FDA Did

The final guidance. The notice of availability (91 FR 43101–43103, 14 July 2026) states that the FDA is announcing “a final guidance for industry titled ‘Psychedelic Drugs: Considerations for Clinical Investigations,’” and that it “finalizes the draft guidance of the same title issued on June 26, 2023.” The notice explains that the agency wrote the draft because “interest in the therapeutic potential of psychedelic drugs has been increasing and designing clinical trials to evaluate these compounds presents unique challenges.” The final version gives general considerations for sponsors developing psychedelic drugs for medical conditions, with psychiatric disorders and substance use disorders as the examples. The FDA says it considered the comments received on the 2023 draft and that “a few revisions were made” for clarity. The guidance document itself is dated July 2026 and was prepared by the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research (CDER).

The hearing. The same day, a second notice (91 FR 43095–43098) announced a hybrid (in-person and online) public hearing for 14 September 2026, 12:30 to 4:30 p.m. Eastern Time, at the FDA’s White Oak campus in Silver Spring, Maryland. Its stated purpose is to gather “feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.” The FDA says it is holding the hearing “in collaboration with federal partners.” Registration, including requests to speak, closed at 11:59 p.m. Eastern Time on 21 August 2026, and written comments were accepted until 5 October 2026.

Both notices are signed by the FDA’s Deputy Commissioner for Policy, Legislation, and International Affairs.

Back to Table of Contents

2. What a Guidance Is, and the Terms It Uses

• Guidance. An FDA guidance describes the agency’s current thinking on a topic. The notice states that this one “does not establish any rights for any person and is not binding on FDA or the public,” and that a sponsor “can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.” The guidance itself explains that the word “should” in an FDA guidance means something is suggested or recommended, not required. Each page of the document is headed “Contains Nonbinding Recommendations.”
• Psychedelic drug. The guidance uses the term as shorthand for “classic psychedelics,” typically understood to be drugs that activate the brain’s serotonin 5-HT2A receptor, such as psilocybin and LSD, and for “entactogens or empathogens” such as MDMA. It says the same concepts may apply to other products that cause perceptual disturbances and altered consciousness.
• Sponsor and IND. A sponsor is the company, institution or researcher responsible for a clinical trial. An investigational new drug application (IND) is the filing that lets a drug not yet approved be tested in people. The guidance applies to trials run under an IND, including research INDs not intended to support a marketing application, and it names academic researchers among the sponsors it addresses.
• Docket. A Federal Register docket is the public file that holds a notice, its background documents and the comments people send in, viewable at regulations.gov under its number. The guidance notice says comments on any guidance may be submitted at any time (21 CFR 10.115(g)(5)).
• Schedule I. Under the Controlled Substances Act, Schedule I covers substances with a high potential for abuse and no currently accepted medical use in treatment in the United States. The guidance notes that many psychedelic drugs are in Schedule I.

The guidance’s background section says psychedelic drug programs are held to “the same regulations and same evidentiary standards for approval as other drug development programs,” while noting features that complicate study design: intense perceptual disturbances and altered consciousness lasting “several hours or days,” programs that pair the drug with a psychological intervention, and investigators’ hypothesis that one or a few doses may give rapid and lasting benefit. Because experience in this area is limited, the FDA writes that rather than giving specific study-design recommendations, the guidance presents “foundational constructs.”

Back to Table of Contents

3. Manufacturing and Product Quality

The guidance restates the legal requirement that sponsors provide enough chemistry, manufacturing and controls information to establish the identity, quality, purity and strength of the drug at every phase of clinical trials (21 CFR 312.23(a)(7)). Points it makes specifically for psychedelics:

• A product made from plant material, algae or macroscopic fungi (mushrooms) may count as a botanical drug under the FDA’s 2016 botanical drug guidance. Products that are genetically modified, made by fermentation in yeast, bacteria or plant cells, or highly purified from natural sources are not treated as botanicals for this purpose.
• Drugs must be made under current good manufacturing practice (CGMP). The guidance notes that drug product used in phase 2 studies, the first studies that measure effectiveness, must be manufactured under CGMP requirements.
• Chemistry data held by another party may be proprietary; a sponsor either submits its own information or relies on another party’s file with written permission (a “right of reference”).

Back to Table of Contents

4. Animal Studies and the Heart-Valve Question

Nonclinical (laboratory and animal) testing follows the international ICH M3(R2) guidance, with considerations the FDA calls possibly unique to psychedelics because some programs rely on prior human experience:

• Psychedelic drugs without a history of adequate human exposure are, in the guidance’s words, not to be “tested in humans until safety has been established in nonclinical studies.” The FDA encourages data from new approach methodologies (non-animal methods) where appropriate.
• Where adequate human exposure and information already exist from earlier clinical studies and no serious safety concerns were identified, the guidance says it may be reasonable to begin clinical studies without standard animal toxicology testing.
• If repeat dosing is expected, studies supporting chronic or repeated intermittent dosing are part of the program.
• Heart valves. The guidance states that the 5-HT2B serotonin receptor subtype “has been linked to heart valvulopathy in humans,” citing a 2011 review (Hutcheson et al., listed under Key Research Papers). Sponsors are asked to test whether a drug activates that receptor; if it does, repeat-dose animal studies include a microscopic examination of all heart valves for thickening. Validated computer models (QSAR) are mentioned as supporting evidence.

Back to Table of Contents

5. How the Body Handles the Drug: Food, Interactions and Organ Function

The clinical pharmacology section covers how the drug is absorbed, distributed and cleared (pharmacokinetics) and what it does in the body (pharmacodynamics). The guidance lists:

• the effect of a high-fat meal on an oral psychedelic, studied early in development;
• the effect of other factors on drug levels, used to set who can enroll and which medicines are prohibited during a trial;
• for drugs that activate 5-HT2B, the statement that long-term exposure “may induce cardiac valve stiffening,” and that the FDA currently recommends excluding people with existing valve disease (valvulopathy) or pulmonary hypertension from multiple-dose studies until the risk is better characterized;
• studies in people with impaired kidney or liver function, to inform dose adjustments and labeling.

On drug interactions, the guidance says more research is needed and lists examples from published studies of LSD:

• Taking selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs) for 3 weeks or more may reduce the subjective effects of psychedelic drugs.
• Taking tricyclic antidepressants or lithium for 3 weeks or more may strengthen those effects, “creating a potential psychiatric safety concern”; SSRIs, SNRIs or MAOIs taken for less than 3 weeks may also strengthen them.
• MAOIs combined with MDMA or other amphetamine-based psychedelics “can produce a life-threatening hypertensive crisis” (a dangerous rise in blood pressure).

The two LSD studies the guidance cites (Bonson et al. 1996; Bonson and Murphy 1996) are listed under Key Research Papers.

Back to Table of Contents

6. Abuse Potential and Controlled-Substance Rules

Any new drug that acts on the central nervous system is assessed for abuse potential. For psychedelics the guidance states:

• An abuse potential assessment and a proposal for scheduling under the Controlled Substances Act are required parts of a new drug application. If a Schedule I psychedelic were approved, that assessment would help decide which schedule it moves to. A footnote explains that once the FDA approves a drug, it has a currently accepted medical use and is placed in Schedule II through V.
• Trials of Schedule I psychedelics must comply with Drug Enforcement Administration (DEA) rules on research, manufacturing, import and export, handling and storage.
• Self-administration and conditioned place preference studies in animals are “not usually required for psychedelic drugs because they typically do not produce positive signals in those studies.” A human abuse potential study may not be scientifically necessary for some psychedelics whose effects are already well characterized and for which robust epidemiological data exist.
• Expected psychoactive effects such as euphoria, hallucinations and changes in thinking are to be recorded as adverse events because of their link to abuse potential, “even if subjects do not describe these effects as adverse,” and even if they are thought to be part of the therapeutic response.
• For a drug already used recreationally or for unapproved medical purposes, an application includes a systematic review of the scope of abuse and associated harms.

Back to Table of Contents

7. Trial Design: Blinding, Controls and How Long Benefits Last

The guidance identifies functional unblinding as the central design problem. In a blinded trial neither participants nor staff are meant to know who received the active drug, but the intense perceptual changes psychedelics cause usually reveal it. The FDA explains that this can create expectation bias in both directions: people who notice strong effects may expect to improve, and people on placebo who notice none may expect not to. Points in this section:

• Controls. An inert placebo can be “problematic for assessing efficacy” even though it gives better context for safety findings. Alternatives the guidance names include lower doses of a psychedelic or other psychoactive drugs that mimic parts of the experience; the agency “encourages the consideration of innovative approaches for control groups.”
• Reducing bias. Central raters blinded to treatment and visit number; questionnaires asking participants and staff which treatment they think was given, with how certain they are; and questionnaires measuring participants’ expectations before randomization and at the end of treatment.
• Durability. Because the target conditions typically last months or years, the guidance asks sponsors to evaluate how long a response lasts and the safety and efficacy of repeat dosing. For a chronic illness such as PTSD or major depressive disorder, it describes a double-blind evaluation at 12 weeks before an initial application, continued follow-up beyond week 12, and, as “the most informative” design, blinded follow-up typically of 12 months with prespecified criteria for retreatment.
• Dose and complementary trials. Characterize the dose–response relationship early. One example pairs a low/middle/high-dose trial without placebo (less unblinding) with a placebo-controlled trial (better safety signals).
• Who enrolls. People with prior psychedelic experience are more likely to recognize the effects; the guidance says including some is reasonable but they are not to be overrepresented, and randomization is stratified by prior use. It also states that trials should not unnecessarily exclude groups (for example by age or pregnancy) who are intended to receive the treatment after approval, and notes that excluded populations may not be described in the approved indication.

A 2021 review of blinding and expectancy in psychedelic trials (Muthukumaraswamy et al.) is listed under Key Research Papers for background on this problem; it is not cited in the guidance.

Back to Table of Contents

8. Psychotherapy Alongside the Drug

Many programs give the drug together with psychological support or psychotherapy, during the drug session or separately. The guidance says this extra variable “both complicates the assessment of effectiveness and presents a challenge for any future product labeling.” It states:

• “As of the publication date of this guidance, the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.” A factorial design (testing drug and therapy separately and together) is named as one way to separate the two.
• A therapist monitoring a session can usually tell which treatment was given; one option offered is for the in-session monitor not to take part in later psychotherapy.
• Sponsors describe their treatment model and the reason for it, and any design features meant to reduce bias or measure the therapy’s share of the effect. The model used in trials may appear in product labeling.

Back to Table of Contents

9. Safety Monitoring During Treatment Sessions

The guidance notes that the FDA may place a study on clinical hold if participants would face “an unreasonable and significant risk of illness or injury” (21 CFR 312.42), and that people given a psychedelic “may remain in a vulnerable state for several hours or longer.” It states that the agency expects safety monitoring to include:

• Two monitors for the whole session: a lead monitor who is a health care provider with graduate-level training and clinical experience in psychotherapy, licensed to practise independently; and an assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health setting.
• If the lead monitor is not a physician, a licensed on-call physician able to reach the site within 15 minutes in a medical emergency.
• Informed consent that describes changes in perception, cognition and judgment that persist for many hours, and “increased vulnerability and suggestibility during the treatment session.”
• Documentation of all central nervous system effects throughout the session, including expected ones, whether experienced as positive, neutral or negative.
• For drugs with a history of human use, a systematic literature review of adverse events seen in recreational or unapproved use, which then become predefined adverse events of special interest.
• Assessment of effects on orientation, thinking and perception over time, to inform monitoring, discharge and driving; a formal driving study is mentioned as something to consider.
• For drugs active at 5-HT2B that would be given chronically, echocardiograms of heart valves and pulmonary artery pressure at baseline and follow-up. The guidance adds that because psychedelic dosing schedules are not yet established, it is unclear whether this applies, but people with existing valve disease or pulmonary hypertension are excluded until the cardiac risk is characterized. QT interval and blood pressure assessment follow the ICH E14 guidance and a 2022 draft guidance on pressor effects.

Looking past trials, the guidance anticipates that more safety assessment may be needed after approval, when more people would be exposed, and asks sponsors to consider whether a risk evaluation and mitigation strategy (REMS), a set of required safety measures, may be needed. It says the FDA may weigh public health effects, including risks of nonmedical use, substance use disorder, accidental exposure and overdose, in its overall benefit–risk assessment.

Back to Table of Contents

10. The April 2026 Actions That Came First

On 18 April 2026 the President signed Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness” (91 FR 21709, 22 April 2026). The July hearing notice describes it as establishing “a policy of accelerating innovative research models and appropriate drug approvals to help increase access to psychedelic drugs for serious mental illness,” and as directing HHS and the FDA to work with other agencies to increase trial participation, data sharing and real-world evidence on psychedelic drugs.

An FDA news release of 24 April 2026, “FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order,” announced:

• National priority vouchers to three programs, studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder (PTSD). The hearing notice explains that these vouchers are designed to shorten review times for qualifying applications that align with national health priorities.
• A noribogaine study. The FDA allowed an early-phase (phase 1) clinical study of noribogaine hydrochloride, a derivative of ibogaine, to proceed under an IND as a potential treatment for alcohol use disorder. The release calls this the first time the FDA has allowed a U.S. clinical study of an ibogaine derivative, and states: “The FDA’s decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective.”
• The coming final guidance. The release said the FDA intended to release the final psychedelics guidance “imminently”; it was published on 14 July.

In the release, the FDA Commissioner said these medications “have the potential to address the nation’s mental health crisis” and that “it is critical that their development is grounded in sound science and rigorous clinical evidence.” The Acting Director of CDER said: “At the FDA we are showing our support of investigating the safety and efficacy of this class of drugs through today’s actions.”

Back to Table of Contents

11. The September 2026 Public Hearing

A Part 15 hearing (21 CFR part 15) is an informal FDA proceeding in which members of the public present information and views to a panel; the rules of evidence do not apply and only the presiding officer and panel members may ask questions. The notice says the panel would include CDER subject-matter experts and panelists from federal partner agencies, and that the hearing would be transcribed, with the transcript posted on regulations.gov.

The FDA asked for input on four topics concerning use of psychedelic drugs “in supervised and supportive settings”:

1. Provider training and credentialing: the evidence base for training curricula; staffing and roles by phase of care (screening and preparation, administration and monitoring, follow-up), including non-prescriber staff such as licensed counselors and peer support specialists; care coordination; and licensure, supervision and practice-hour requirements.
2. Patient safety: patient education, side-effect assessment and “set and setting (i.e., mindset and environment)”; informed-consent topics including “the potential for an amplified power imbalance between patient and provider, the use of therapeutic touch, and the risk of psychological distress or a challenging psychedelic experience”; screening for conditions linked to worse outcomes (for example cardiovascular disease, psychosis or suicidality); preventing diversion and nonmedical use of any drug once approved; detecting and reporting ethical violations by practitioners; and monitoring and follow-up, including links to emergency and crisis services.
3. Access: evidence needed for insurance coverage and payment, provider–payer coordination, clinic capacity (workforce, space, scheduling, storage, security) and telehealth.
4. Data collection: registries for real-world safety, linking data sources (health records, claims, pharmacy data, adverse event reports, surveys and state psychedelic programs) to describe medical and nonmedical use, common data elements, and how adverse events are defined given both acute and long-term effects.

The notice says some of these topics fall under the authority of other federal agencies or of states, and that the FDA “does not intend this notice to suggest FDA regulatory action outside our statutory authority.” Speakers had to disclose financial relationships with entities developing or providing psychedelic products or services, and no commercial or promotional material was permitted. The FDA said written comments would be weighed “equally with oral presentations.”

Back to Table of Contents

12. What These Documents Do Not Do

• No approval. The guidance approves no psychedelic drug and sets no legally enforceable requirement; it is a set of nonbinding recommendations for designing trials, and the FDA writes that it is “not binding on FDA or the public.”
• No set dose or eligibility list. The guidance says it gives foundational considerations “rather than providing specific recommendations on study design,” and that the FDA “does not address inclusion and exclusion criteria in this guidance.”
• No decision on access. The hearing collects views; it is not a decision on how, or whether, psychedelic drugs would be used in practice.
• No safety or effectiveness finding. The hearing notice states that neither a national priority voucher nor a Breakthrough Therapy designation “constitutes an FDA determination of safety or effectiveness,” and neither substitutes for marketing approval. The April release says the same of the noribogaine study.
• Topics outside the hearing. The FDA said it was not seeking comment on: the safety or effectiveness of any particular product or pending application; the scheduling status of any substance under the Controlled Substances Act; legalization or decriminalization, or the merits of state or local programs (though it welcomed input on data collection from such programs); religious, ceremonial or personal (non-medical) use; and individual disputes, enforcement matters or complaints about specific practitioners or entities.

Back to Table of Contents

13. Status as of 11 October 2026

• Final guidance: final, in effect as FDA current thinking since 14 July 2026, and nonbinding. Comments on it can still be sent to Docket No. FDA-2023-D-1987 at any time.
• Public hearing: scheduled for 14 September 2026; registration closed 21 August 2026; the comment period on Docket No. FDA-2026-N-7542 closed at 11:59 p.m. Eastern Time on 5 October 2026, and the notice states that later comments will not be considered. The documents used for this page do not report what was said at the hearing or any action taken on it.
• April actions: the vouchers and the noribogaine study clearance are regulatory steps on development programs; none is an approval.

Back to Table of Contents

14. How It Fits the FDA’s Earlier Steps

• 2017–2019: Breakthrough Therapy designations. The July hearing notice records that the FDA granted Breakthrough Therapy designation to MDMA for PTSD (2017) and to psilocybin for treatment-resistant depression (2018) and for major depressive disorder (2019). This designation speeds development and review of drugs for serious conditions where early clinical evidence suggests a substantial improvement over available treatment.
• 26 June 2023: the draft guidance. The FDA published the draft “Psychedelic Drugs: Considerations for Clinical Investigations” (88 FR 41407, Docket No. FDA-2023-D-1987), the document finalized in July 2026.
• April 2026: Executive Order 14401 (18 April) and the FDA actions of 24 April described in section 10.
• 14 July 2026: final guidance and hearing notice, described above.
• 5–6 October 2026: ibogaine request for information. The FDA announced, and on 6 October published (91 FR 63563, Docket No. FDA-2026-N-10429), a request for information on the design of early clinical trials of ibogaine. That notice says it builds on the July final guidance and applies it to one compound with a documented heart-rhythm risk. It is described on the site’s FDA Ibogaine Research Notice (2026) page.

Read in sequence, the documents move from general to specific: the 2023 draft and 2026 final guidance set out considerations for every psychedelic trial; the April actions advanced particular development programs; the hearing asked how supervised use might work if a product were approved; and the ibogaine notice applied the guidance to a single substance.

Back to Table of Contents

15. Primary Documents

1. Food and Drug Administration, HHS (2026). Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability. Federal Register 91:43101–43103, 14 July 2026. Docket No. FDA-2023-D-1987 — FR Doc. 2026-14158
2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2026). Psychedelic Drugs: Considerations for Clinical Investigations. Guidance for Industry, July 2026 — guidance PDF, fda.gov. The FDA’s landing page for the guidance is at www.fda.gov/regulatory-information/ (FDA guidance documents) /psychedelic-drugs-considerations-clinical-investigations.
3. Food and Drug Administration, HHS (2026). Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments. Federal Register 91:43095–43098, 14 July 2026. Docket No. FDA-2026-N-7542; hearing 14 September 2026 — FR Doc. 2026-14155
4. U.S. Food and Drug Administration (2026). FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order. FDA News Release, 24 April 2026 — fda.gov press announcement
5. Food and Drug Administration, HHS (2023). Psychedelic Drugs: Considerations for Clinical Investigations; Draft Guidance for Industry; Availability. Federal Register 88:41407, 26 June 2023. Docket No. FDA-2023-D-1987 — FR Doc. 2023-13428

Back to Table of Contents

Key Research Papers

1. Hutcheson JD, Setola V, Roth BL, Merryman WD (2011). Serotonin receptors and heart valve disease — it was meant 2B. Pharmacology & Therapeutics 132(2):146-157 — PubMed PMID: 21440001
2. Bonson KR, Buckholtz JW, Murphy DL (1996). Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425-436 — PubMed PMID: 8726753
3. Bonson KR, Murphy DL (1996). Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behavioural Brain Research 73(1-2):229-233 — PubMed PMID: 8788508
4. Muthukumaraswamy SD, Forsyth A, Lumley T (2021). Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology 14(9):1133-1152 — PubMed PMID: 34038314
5. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384(15):1402-1411 — PubMed PMID: 33852780
6. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 387(18):1637-1648 — PubMed PMID: 36322843
7. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27(6):1025-1033 — PubMed PMID: 33972795

The first three papers are cited in the final guidance itself. The remaining four are published trials and a methods review on the drug classes and conditions the guidance and hearing address; they are listed as background and are not cited in the FDA documents.

PubMed Topic Searches

1. PubMed: functional unblinding in psychedelic clinical trials
2. PubMed: psilocybin and depression, randomized trials
3. PubMed: 5-HT2B agonists and valvular heart disease
4. PubMed: psychedelic drug interactions with antidepressants

Back to Table of Contents

Connections

• FDA and Regulation
• FDA Ibogaine Research Notice (2026)
• 7-OH Kratom Products: The 2026 Scheduling Steps
• Ibogaine: History, Pharmacology and Safety
• Albert Hofmann
• Albert Hofmann: Sacred Mushrooms and Morning Glory Seeds
• Post-Traumatic Stress Disorder (PTSD)
• Depression
• Alcohol Use Disorder
• Addiction
• Methylene Blue: Drug Interactions and Serotonin Syndrome

Back to Table of Contents